Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria.
COVID-19 related urticaria
cytokine storm
steroids and antihistamines
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
pubmed:
11
7
2020
medline:
8
4
2022
entrez:
11
7
2020
Statut:
ppublish
Résumé
Dermatologists around the world are still doing their best to report more cutaneous manifestations of the emerging COVID-19 infection. New-onset acute or relapsing chronic urticaria may result from the body's overreacting inflammatory response to infection. The cytokine storm hits different organs in the body, including the skin, leading to activation and degranulation of mast cells with resultant urticaria. Low-dose systemic steroids combined with antihistamines can combat the COVID-19 inflammatory insult and play a role in the control of COVID-19 related severe urticarial attack.
Identifiants
pubmed: 32649228
doi: 10.1080/09546634.2020.1795062
doi:
Substances chimiques
Histamine Antagonists
0
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140-1141Commentaires et corrections
Type : CommentIn